| Not Yet Recruiting | ICRA Randomised Controlled Trial NCT07068464 | NHS Grampian | Phase 3 |
| Active Not Recruiting | An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian NCT07096583 | Anhui Provincial Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | No-Stoma Policy in Advanced Ovarian Cancer Surgery NCT07213193 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | GYNecologic Cancer-Related COGnitive Impairment NCT06662435 | Northwestern University | N/A |
| Recruiting | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer NCT06617923 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Multimedia Aid for Genetic Testing in Gynecologic Oncology NCT07084168 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | RC48 in Combination With AK104 and Bevacizumab in OCCC NCT06540729 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy NCT06268665 | University of California, Davis | Phase 2 |
| Recruiting | The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women NCT06556342 | Tongji Hospital | N/A |
| Not Yet Recruiting | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours NCT06329323 | Imperial College London | — |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Unknown | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors NCT06256055 | UTC Therapeutics Inc. | Phase 1 |
| Recruiting | Mesenteric Infiltration in Ovarian Cancer NCT06331130 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy NCT05990426 | Northwestern University | N/A |
| Recruiting | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib NCT05887609 | University of Colorado, Denver | Phase 2 |
| Recruiting | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) NCT05743517 | Northwestern University | N/A |
| Recruiting | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or Hig NCT05080556 | University College, London | Phase 2 |
| Completed | Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy NCT06161233 | Istituti Clinici Scientifici Maugeri SpA | N/A |
| Active Not Recruiting | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention NCT05677048 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study NCT06800105 | University of Tennessee Graduate School of Medicine | — |
| Withdrawn | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced NCT05465590 | Mainline Biosciences, Inc. | EARLY_Phase 1 |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker NCT05763511 | University of Aarhus | — |
| Recruiting | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) NCT05403177 | University Health Network, Toronto | — |
| Unknown | Gynaecology Exercise and Mindfulness Study NCT05561413 | University of Ulster | N/A |
| Recruiting | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastat NCT05296564 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid NCT05252390 | Nuvation Bio Inc. | Phase 1 |
| Terminated | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in NCT05200364 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors NCT05187338 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of O NCT05059782 | Xi'an Jiaotong University | N/A |
| Unknown | The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib NCT05081765 | Poznan University of Medical Sciences | — |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Unknown | Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1 NCT04523116 | University of Manchester | — |
| Completed | Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK NCT04532645 | AstraZeneca | — |
| Completed | KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovativ NCT05256576 | Charite University, Berlin, Germany | N/A |
| Active Not Recruiting | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Healt NCT04000880 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors NCT04205227 | ENB Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Canc NCT03748186 | Sutro Biopharma, Inc. | Phase 1 |
| Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681 | Boston Scientific Corporation | — |
| Terminated | Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy NCT03740984 | Dr. Horst Schmidt Klinik GmbH | N/A |
| Completed | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory NCT03199586 | Novita Pharmaceuticals, Inc. | Phase 1 |
| Completed | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery NCT02997553 | Institut de Cancérologie de Lorraine | Phase 3 |
| Completed | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. NCT03245736 | Seagen Inc. | Phase 2 |
| Terminated | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian NCT03162562 | CanariaBio Inc. | Phase 1 |
| Completed | An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surger NCT03011320 | Endocyte | Phase 1 |
| Completed | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignanci NCT03384511 | Shandong Cancer Hospital and Institute | Phase 4 |
| Terminated | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors NCT02669914 | Washington University School of Medicine | Phase 2 |
| Completed | MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer NCT02582931 | Washington University School of Medicine | Phase 1 |
| Completed | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors NCT02552121 | Seagen Inc. | Phase 1 / Phase 2 |
| Terminated | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines NCT02432378 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor NCT02069158 | Cristiana Sessa | Phase 1 |
| Completed | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors NCT02001623 | Seagen Inc. | Phase 1 / Phase 2 |
| Completed | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal NCT00193297 | SCRI Development Innovations, LLC | Phase 2 |